Overview
Zynex Q3 revenue fell 73% yr/yr, missing analyst expectations
Company reported a Q3 net loss of $42.9 mln, impacted by asset impairment charges
Outlook
Zynex exploring strategic alternatives, including capital raising and restructuring
Company enters 30-day grace period for $1.5 mln interest payment
Result Drivers
TRICARE PAYMENT SUSPENSION - Revenue decline attributed to Tricare payment suspension and $2.8 mln revenue reduction during suspension period
CLAIM SUBMISSION CHANGES - Changes to payer claim submissions and review practices led to denials and payment delays, impacting revenue
WORKFORCE REDUCTIONS - Workforce reductions in early 2025 negatively impacted device orders, new patient onboarding, and revenue
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $13.40 mln | $23.02 mln (2 Analysts) |
Q3 EPS | -$1.42 | ||
Q3 Net Income | -$42.90 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Zynex Inc is $2.85, about 80.1% above its November 14 closing price of $0.57
Press Release: ID:nPn6Ry2tfa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)